NLA 2026 at a glance
NLA 2026 highlights a shift in lipid management from risk recognition toward earlier, more precise intervention. Emerging therapies, genetic screening, imaging-guided prevention and evolving treatment strategies are bringing new competitive considerations into focus.
LucidQuest examines the clinical and industry developments that could influence lipid management, cardiovascular prevention and competitive positioning.
📅 Build your schedule around the topics that matter most.
📥 Download the NLA 2026_Preview_by_LucidQuest
NLA 2026: Key Developments in Lipid Management
Lp(a) Testing: Screening and Risk Assessment Gain Importance
Lp(a) screening, risk assessment and management strategies remain central topics as clinicians await dedicated Lp(a)-lowering therapies.
The discussions will focus on identifying elevated risk and improving management strategies ahead of the availability of targeted treatments.
ApoC-III Inhibition: Emerging Therapies Could Reshape Triglyceride Management
TRYNGOLZA and plozasiran sessions will highlight the potential role of ApoC-III-targeted therapies in familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia.
These developments may influence treatment positioning in rare triglyceride disorders.
Primary Prevention: Earlier LDL-C Lowering Gains Strategic Attention
VESALIUS-CV, FOURIER, ODYSSEY Outcomes and clinical experience with PCSK9-targeted therapies will reinforce interest in earlier LDL-C lowering before cardiovascular events.
The discussions will examine the role of intensive LDL-C reduction in cardiovascular prevention.
Genetic Risk: Screening and Emerging Technologies Move Closer to Routine Care
Familial hypercholesterolemia (FH) screening, cascade testing, polygenic risk scores and CRISPR-based approaches will highlight the growing relevance of genetic risk assessment in lipid management.
These developments could influence how genetic information is incorporated into clinical decision-making.
Imaging-Guided Prevention: Risk Stratification Expands Beyond Traditional Calculators
Coronary computed tomography angiography (CCTA), plaque analysis, coronary calcium assessment and digital risk tools may expand cardiovascular risk stratification beyond traditional risk calculators.
These approaches highlight opportunities for more personalized prevention and earlier intervention.
Lipid Management Competitive Landscape: Competitor and Industry Signals
Oral PCSK9 Inhibition: MSD’s Enlicitide Advances Competitive Positioning
Phase 3 CORALreef data for enlicitide will provide an important update on oral PCSK9 inhibition and its potential positioning in heterozygous familial hypercholesterolemia (HeFH).
The findings will inform its competitive positioning relative to established injectable PCSK9 therapies.
ApoC-III Inhibition: Ionis Positions TRYNGOLZA in Rare Triglyceride Disorders
Severe hypertriglyceridemia programming involving Ionis Pharmaceuticals’ TRYNGOLZA will continue to highlight the role of ApoC-III inhibition in rare triglyceride disorders.
FCS Treatment: Arrowhead Highlights Plozasiran
FCS-focused education involving Arrowhead Pharmaceuticals’ plozasiran will reinforce triglyceride reduction as a strategic focus area.
Primary Prevention: Amgen’s Evolocumab and VESALIUS-CV
VESALIUS-CV discussions involving Amgen’s evolocumab will support broader consideration of intensive LDL-C lowering in high-risk primary prevention populations.
Imaging-Guided Prevention: Heartflow Focuses on Personalized Risk Assessment
Heartflow’s CCTA and plaque analysis technologies will be positioned as tools supporting personalized cardiovascular prevention and earlier intervention.
What to Watch After NLA 2026: Clinical Evidence and Competitive Differentiation
LucidQuest will monitor five developments:
- Earlier LDL-C lowering: Whether VESALIUS-CV discussions strengthen support for intensive LDL-C reduction in primary prevention populations.
- Oral PCSK9 competition: Whether enlicitide Phase 3 results improve its positioning against established injectable PCSK9 therapies.
- ApoC-III inhibition: Whether TRYNGOLZA and plozasiran evidence further supports ApoC-III inhibition in FCS and severe hypertriglyceridemia.
- Lp(a) screening: Whether testing initiatives and apheresis discussions accelerate the adoption of routine screening.
- Precision prevention: Whether polygenic risk scores and imaging-guided tools demonstrate sufficient clinical utility to influence lipid management.
Download the NLA Preview Report
Download LucidQuest’s NLA 2026 preview report for deeper analysis of emerging lipid-lowering therapies, clinical developments, competitor positioning and the strategic trends shaping cardiovascular prevention.
📅 Build your schedule around the sessions that matter most.
📥 Download the NLA 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
